Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Biotechnology

Healthcare
$7.01 -3.62%

-$0.34 today

Market cap
$158.87M
Beta
0.82
P/E (TTM)
-1.0
EPS (TTM)
-$8.86
52W Low $3.65High $10.99

Volume 0.67M

Average 0.85M

KPTI Income Before Tax

Profit after all operating and non-operating items but before income tax.

Karyopharm Therapeutics Inc.NASDAQ: KPTI

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$22.39M, compared with -$23.43M a year earlier. Trailing-twelve-month income before tax was -$194.96M.

Context

  • Income before tax amounted to 134.2% of revenue in FY2025, up 81.6 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$22.39M or moves back toward the trailing-twelve-month quarterly average of -$48.74M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$22.39M+78.1% QoQ
Last fiscal yearDec 2025
-$196M-156.7% YoY
LTMMar 2026
-$194.96M-211.9% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.4%——
1 year-156.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(196M) USD
Year-over-year change
-156.7%

Income Before Tax vs competitors

How KPTI compares with its peers on the latest reported figures

  • KPTI's LTM Mar 2026 income before tax of -$194.96M is the lowest of the 4 companies compared; the peer median is -$41.6M.
  • Its year-over-year change of -211.9% is the 3rd highest of 4, against a peer median of -2.0%.
  • Income before tax amounts to 129.0% of revenue for KPTI, versus a peer median of 1106.2%.
KPTI Competitors Peer median
Income Before Tax for KPTI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026-$9.22M +26.3%——
INMBINmune Bio, Inc.LTM Mar 2026-$41.6M -2.0%——
XFORX4 Pharmaceuticals, Inc.LTM Mar 2026-$99.72M -768.2%—1106.2%
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026-$194.96M -211.9%—129.0%
Peer median (excluding KPTI) -$41.6M-2.0%—1106.2%

Competitors are the stored peer set for KPTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue209.82M157.07M146.03M145.24M146.07M
Cost of Revenue3.4M5.21M4.94M6.01M5.95M
Gross Profit206.42M151.86M141.09M139.23M140.12M
Gross Margin98.4%96.7%96.6%95.9%95.9%
Research & Development160.84M148.66M138.75M143.23M125.62M
Selling, General & Admin143.85M145.4M131.88M115.44M105.21M
Operating Expenses304.69M294.06M270.63M258.67M230.83M
Depreciation & Amortization789K621K530K340K296K
EBITDA(96.99M)(139.31M)(118.42M)(38.6M)(149.85M)
EBITDA Margin-46.2%-88.7%-81.1%-26.6%-102.6%
Operating Income(98.27M)(142.2M)(129.54M)(119.44M)(90.71M)
Operating Margin-46.8%-90.5%-88.7%-82.2%-62.1%
Interest Income582K2.36M10.94M7.4M2.77M
Interest Expense26.05M25M23.82M37.42M45.85M
Other Income / Expenses(25.55M)(22.72M)(13.24M)43.08M(105.29M)
Income Before Tax(123.82M)(164.92M)(142.78M)(76.37M)(196M)
Pre-Tax Margin-59.0%-105.0%-97.8%-52.6%-134.2%
Income Tax Expense268K369K323K57K43K
Net Income(124.09M)(165.29M)(143.1M)(76.42M)(196.04M)
Net Margin-59.1%-105.2%-98.0%-52.6%-134.2%
EPS (Basic)(24.75)(30.28)(18.79)(9.41)(17.93)
EPS (Diluted)(24.75)(30.28)(18.79)(9.41)(17.93)
Weighted Avg Shares5.01M5.46M7.61M8.12M10.94M
Weighted Avg Shares (Diluted)5.01M5.46M7.61M8.12M10.94M

Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Intrinsic Alpha fair value

Locked

Current Price

$7.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.